Participate in Oracle Customer Programs
AC Medical Inc. helps pharmaceutical companies develop new medicines faster by offering more efficient and accurate ways to capture clinical data. Its core services include clinical trial monitoring and quality control, data management, statistical analysis, auditing, and medical writing. AC Medical is the contract research organization (CRO) division of the Agrex Group, a business process outsourcing and systems development company.
“One of the main challenges facing pharmaceutical companies is how to launch new, innovative products to the market as quickly as possible while reducing the time it takes to research and develop new medications,” said Yukio Watanabe, director, sales department, AC Medical Inc.
In 2006, AC Medical started offering services using Oracle Health Sciences InForm GTM On Demand to pharmaceutical companies when many of them were still capturing data in paper-based reports. AC Medical realized that the Oracle solution could help these companies develop and release new products faster and increase their sales by automating the process of collecting clinical data.
Oracle Health Sciences InForm GTM On Demand is being used in more than 115 countries, and this strong global record is one of its main competitive advantages when AC Medical proposes the electronic data capturing solution to pharmaceutical companies.
“The strong integration between Oracle products was the most compelling reason for choosing Oracle. For example, we may be able to use Oracle’s reporting tool to display analysis results visually,” said Hirokazu Hashiba, manager, data management department, data science division, AC Medical Inc.
“There’s also a strong sense of trust in the Oracle product line-up,” said Koji Osato, deputy director, data management department, data science division, AC Medical Inc. “Oracle Health Sciences InForm GTM On Demand is well-known overseas and has strong global potential due to features such as multilingual capability and interoperability with other applications.
“I’d like to see this system being used in the Asian market, where computerized clinical trials are set to increase in the future,” he said.